ZNTL: Azenosertib advances toward accelerated approval in ovarian cancer with robust clinical and regulatory momentum
Azenosertib is advancing through late-stage trials for platinum-resistant ovarian cancer, showing strong efficacy and safety in Cyclin E1-positive patients. Regulatory feedback supports the accelerated approval pathway, with commercial preparations and global expansion underway. Cash reserves exten…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.